Excellent Response to Olaparib in a Patient With Metastatic HR+/HER2− Breast Cancer With BRIP1 Mutation
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Excellent response to olaparib in metastatic HR-positive, HER2-negative breast cancer with BRIP1 mutation
Ann. Oncol 2023 Mar 01;34(3)315-318, D Kwapisz, B Verret, C Garcia, F AndréFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.